Barclays said it believes the recent pullback related to tensions in the Middle East has improved Align Technologies’ risk-reward profile. The bank upgraded the orthodontic company from equal weight to overweight. Analyst Glenn Santangelo’s $200 price target suggests the stock could rise 18% from Monday’s closing price. ALGN 1Y Mountain ALGN 1Y Chart Santangelo noted that the stock reached $197 in early February following Align’s strong fourth-quarter results and the release of its fiscal 2026 outlook. However, stock prices fell sharply in a broader market decline. “The Middle East conflict has caused a 15% decline from recent February highs, improving risk and return. Indeed, if the conflict drags on, our calls may prove premature,” the analyst said. “However, as it trades at 10x EBITDA, we believe ALGN is well-positioned to benefit post-dispute.” Santangelo pointed to Align’s fourth-quarter results suggesting new momentum for the business. What was also impressive, he wrote, was Align’s balance across market segments and geographies. The analyst added that website traffic to both the Align homepage and My Invisalign page suggests that last quarter’s positive trends continued this quarter. “We are encouraged by the continued strength of the data, especially as consensus is forecast for a sequential 2.4% revenue decline from Q4 to Q1,” he added. Santangelo said Align’s revenue exposure to the Middle East is in the single digits and the company has a manufacturing facility in Israel. “As of Friday, the facility continues to operate and is not affected by the ongoing dispute. While we do not believe there has been a material impact on the company’s financial outlook at this time, we appreciate the fluidity of the situation,” he wrote.
